Detalles de la búsqueda
1.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707688
2.
Systematic Modeling and Design Evaluation of Unperturbed Tumor Dynamics in Xenografts.
J Pharmacol Exp Ther
; 366(1): 96-104, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29691287
3.
Characterizing Gemcitabine Effects Administered as Single Agent or Combined with Carboplatin in Mice Pancreatic and Ovarian Cancer Xenografts: A Semimechanistic Pharmacokinetic/Pharmacodynamics Tumor Growth-Response Model.
J Pharmacol Exp Ther
; 360(3): 445-456, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28028124
4.
Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors.
Blood
; 121(18): 3675-81, 2013 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-23509154
5.
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Invest New Drugs
; 32(5): 825-37, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24919854
6.
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer.
Invest New Drugs
; 32(5): 955-68, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24942404
7.
A novel method for assessing in vitro oncology drug combinations using growth rates.
J Biopharm Stat
; 22(3): 496-518, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22416837
8.
Nonclinical assessment of carcinogenic risk and tumor growth enhancement potential of prasugrel, a platelet-inhibiting therapeutic agent.
Int J Toxicol
; 31(4): 317-25, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22692976
9.
Persistence and gazing at humans during an unsolvable task in dogs: The influence of ownership duration, living situation, and prior experience with humans.
Behav Processes
; 201: 104710, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35870551
10.
Addressing Unusual Assay Variability with Robust Statistics.
SLAS Discov
; 26(10): 1291-1297, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34474612
11.
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib.
Oncotarget
; 11(3): 216-236, 2020 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32076484
12.
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
AAPS J
; 21(2): 23, 2019 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706160
13.
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.
Clin Cancer Res
; 25(7): 2278-2289, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563935
14.
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene.
Cancer Discov
; 9(2): 248-263, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30373917
15.
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Eur J Pharm Sci
; 115: 296-303, 2018 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29366960
16.
Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.
Clin Cancer Res
; 24(23): 6028-6039, 2018 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30131386
17.
Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29866156
18.
Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models.
Sci Rep
; 8(1): 15458, 2018 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-30337562
19.
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.
Cell Rep
; 22(11): 2978-2994, 2018 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29539425
20.
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-ß receptor type I inhibitor.
Oncotarget
; 9(6): 6659-6677, 2018 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29467918